Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05021341 · ClinicalTrials.gov registry record · NA

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

A NA study of Glycemia, sponsored by Lindenwood University.

Completed
Registry status
NA
Development phase
5
Enrollment target
1
Study location

NCT05021341: Completed NA study of Glycemia, sponsored by Lindenwood University.

NCT05021341 is a NA study of Glycemia that has completed, run by Lindenwood University. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05021341, a NA study of Glycemia, has completed, sponsored by Lindenwood University.

COMPLETED
Registry status
NA
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the bioavailability of berberine and dihydroberberine and their impact on changes in plasma concentrations of glucose and insulin.

Primary Outcome

Changes in plasma berberine levels after supplementing 500 mg of berberine

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Berberine
  • DIETARY_SUPPLEMENT Dihydroberberine 200
  • DIETARY_SUPPLEMENT Dihydroberberine 100

Study Locations (1)

Missouri

  • Lindenwood University - Saint Charles

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2020-06-22
Est. Completion 2020-11-04
Phase NA
Lindenwood University

29 total trials

What the finished NCT05021341 record still lists

NCT05021341 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Glycemia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT05021341 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT05021341 about?

NCT05021341 is a clinical study titled "Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia". The purpose of this study is to determine the bioavailability of berberine and dihydroberberine and their impact on changes in plasma concentrations of glucose and insulin.

What is the current status of trial NCT05021341?

This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2020-06-22. Estimated completion is 2020-11-04.

What conditions does trial NCT05021341 study?

This clinical trial studies the following conditions: Glycemia.

What interventions are being tested in trial NCT05021341?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Berberine (DIETARY_SUPPLEMENT), Dihydroberberine 200 (DIETARY_SUPPLEMENT), Dihydroberberine 100 (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05021341?

This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05021341 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT05021341's enrollment target sits among peer trials

5 1988th of 2000 higher than 5 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05021341, the US trial registry maintained by the National Library of Medicine. NCT05021341 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.